Citations

Showing 10 of 108104 citations.

Comparative survival and role of STS score in aortic paravalvular leak after SAVR or TAVR: a retrospective study from the USA
Padang, Ratnasari , Ali, Mahmoud , Greason, Kevin L. , Scott, Christopher G. , Indrabhinduwat, Manasawee, Rihal, Charanjit S. , Eleid, Mackram F. , Pellikka, Patricia A. , Pislaru, Sorin V. , Sabbah, Michael S. , Scott, Christopher , Pellikka, Patricia A , Rihal, Charanjit S. , Nkomo, Vuyisile T.

Mayo Clinic

BMJ Open | December 10, 2018 | Volume: 8 | Issue: 12 | Pages: e022437

10.1136/bmjopen-2018-022437 | PMID 30530577 Get It

Objective The presence of aortic paravalvular leak (PVL) is associated with lower survival, but a direct comparison of its impact after transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) has not been performed. This study sought to determine the differential influence of PVL on survival following TAVR versus SAVR and in patients with varying levels of risk as defined by the Society of Thoracic Surgeons (STS) risk score. Methods Patients with and without postprocedural PVL were identified from 2290 patients undergoing TAVR or SAVR at Mayo Clinic between 2008 and 2014. The primary endpoint was overall survival. Results There were 588 patients with PVL (374 TAVR, 214 SAVR): age 78±11 years, 63% male and mean follow-up of 3±2 years. PVL was trivial/mild in 442 (75%) patients. In propensity-matched analyses (n=86 per group), the overall survival at 1 and 4 years was 93% and 56% vs 89% and 61% in patients with PVL after TAVR versus SAVR, respectively (p=0.43). The presence or degree of PVL severity had no influence on survival of patients with high STS score (≥8%), while the presence of greater than mild PVL predicted worse survival in those with STS score <8%. During the first year after PVL diagnosis, while either improvement or stable PVL grade was seen in the majority of patients, worsening of PVL grade was more common in the TAVR group (19%) versus the SAVR group (4%) (p<0.0001). Conclusions At mid-term follow-up, the presence of PVL was associated with equally unfavourable outcomes following SAVR or TAVR. In patients with high STS risk score, the presence of PVL was not independently associated with increased mortality.
Patient-reported activities after bilateral reverse total shoulder arthoplasties
Assenmacher, Andrew T. , Aronowitz, Jessica G., Kergosien, Matthew, Schleck, Cathy D. , Cofield, Robert H. , Sperling, John W. , Alentorn-Geli, Eduard, Aronowitz, Jessica, Sanchez-Sotelo, Joaquin, Alentorn‐Geli, Eduard , Sánchez‐Sotelo, Joaquín

Mayo Clinic

Journal of Orthopaedic Surgery | December 10, 2018 | Volume: 27 | Issue: 1 | Pages: No page available

10.1177/2309499018816771 | PMID 30526285 Get It

Purpose: Reverse shoulder arthroplasty (RSA) improves pain and function with very good satisfaction. Concerns exist about some activities of daily living (ADLs) involving internal rotation. The purpose of this study was to report how patients with bilateral RSA perform various ADLs. Methods: Thirty-one primary bilateral RSA patients (average age 76 years; 21 women and 10 men) completed a survey to assess various outcomes. The average time between the second arthroplasty and the survey was 2.7 years (range 1.0–7.8 years). Results: All clinical parameters were favorable. All patients reported being able to easily manage toileting and 87% reaching their back pocket. However, 29% found difficulty and 39% were unable to wash their back or put on bra. In comparison with various unilateral arthroplasty types, there was no statistical difference in overall activities ( p < 0.05). Conclusion: Bilateral RSA can provide good functional outcome and high satisfaction. Patients manage most ADLs easily with some limitations in activities requiring extreme internal rotation.
CORR Insights®: Are Case Volume and Facility Complexity Level Associated With Postoperative Complications After Hip Fracture Surgery in the Veterans Affairs Healthcare System?
Freedman, Brett A.

Mayo Clinic

Clinical Orthopaedics & Related Research | December 8, 2018 | Volume: 477 | Issue: 1 | Pages: 191-192

10.1097/corr.0000000000000515 | PMID 30531424 Get It

Arterial involvement in Erdheim–Chester disease
Villatoro‐Villar, Michel , Bold, Michael S., Warrington, Kenneth J. , Crowson, Cynthia S. , Goyal, Gaurav , Goyal, Guarav , Warrington, Kenneth J , Shah, Meera , Go, Ronald S. , Koster, Matthew J.

Mayo Clinic

Medicine | December 8, 2018 | Volume: 97 | Issue: 49 | Pages: e13452

10.1097/md.0000000000013452 | PMID 30544428 Get It

Abstract Erdheim-Chester disease (ECD) is a rare histiocytosis of the “L” (Langerhans) group with multisystem involvement that can affect the large and medium-sized arteries mimicking vasculitis. Aortic involvement is common but the frequency and outcome of aortic branch vessel abnormalities are less well described. Patients with ECD were retrospectively identified. Images containing information of arterial involvement within 6 months of diagnosis were considered baseline and compared to last follow-up studies. Two physicians independently reviewed the studies to evaluate for presence of abnormalities attributable to ECD. Age and sex-adjusted logistic regression models were used to examine associations between patient characteristics and vessel involvement at baseline. Among a cohort of 64 patients with ECD, 63 had baseline imaging of vascular structures. ECD involvement of at least 1 segment of the aorta was observed in 56%. Abnormalities were also observed in aortic arch branches (26%), visceral branch arteries (40%), iliofemoral arteries (31%), coronary (5%), and pulmonary (3%) arteries. Perinephric fibrosis was strongly associated with the identification of abnormalities in the thoracic aorta (OR 4.92 [1.54, 15.75]; P = .007), abdominal aorta (OR 7.57 [2.28, 25.07]; P = .001) and visceral branch arteries (OR 6.05 [1.52, 24.03]; P = .01) but not pelvic/lower extremity arteries. Complete normalization of arterial abnormalities at follow-up was only observed in 9% or less of arterial segments involved at baseline. Aortic and aortic branch vessel abnormalities are frequently observed in patients with ECD and are often asymptomatic. Partial and/or complete resolution of arterial findings is uncommon.
Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management
Pardanani, Animesh

Mayo Clinic

American Journal of Hematology | December 8, 2018 | Volume: 94 | Issue: 3 | Pages: 363-377

10.1002/ajh.25371 | PMID 30536695 Get It

AbstractOverviewSystemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MCs) in extra‐cutaneous organs.DiagnosisThe major criterion is presence of multifocal clusters of abnormal MC in the bone marrow. Minor diagnostic criteria include elevated serum tryptase level, abnormal MC CD25 expression, and presence of KITD816V mutation.Risk stratificationEstablishing SM subtype as per the World Health Organization classification system is an important first step. Broadly, patients either have indolent/smoldering SM (ISM/SSM) or advanced SM, the latter includes aggressive SM (ASM), SM with associated hematological neoplasm (SM‐AHN), and mast cell leukemia (MCL). Identification of poor‐risk mutations (ie, ASXL1, RUNX1, SRSF2, NRAS) further refines the risk stratification. Recently, clinical and hybrid clinical‐molecular risk models have been developed to more accurately assign prognosis in SM patients.ManagementISM patients have a normal life expectancy and treatment is generally limited to anaphylaxis prevention/symptom control/osteoporosis treatment. Patients with advanced SM frequently need MC cytoreductive therapy to ameliorate disease‐related organ dysfunction. High response rates have been seen with small‐molecule inhibitors that target mutant‐KIT, including midostaurin (Food and Drug Administration approved) or avapritinib (investigational). Other options for MC cytoreduction include cladribine or interferon‐α, although head‐to‐head comparisons are lacking. Treatment of SM‐AHN primarily targets the AHN component, if an aggressive disease such as acute myeloid leukemia is present. Allogeneic stem cell transplant can be considered in such patients, or in those with relapsed/refractory advanced SM. Imatinib has a limited therapeutic role in SM; effective cytoreduction is limited to those with imatinib‐sensitive KIT mutations.
Neuromuscular transmission defects in myopathies: Rare but worth searching for
Elahi, Behzad , Laughlin, Ruple S. , Litchy, William J. , Milone, Margherita , Liewluck, Teerin , Liewluck, T

Mayo Clinic

Muscle & Nerve | December 8, 2018 | Volume: 59 | Issue: 4 | Pages: 475-478

10.1002/mus.26393 | PMID 30536954 Get It

ABSTRACTIntroduction: Decremental responses in repetitive nerve stimulation have been reported in a few hereditary myopathies. We examined the frequency of decrement in a cohort of myopathy patients. Methods: We reviewed all patients referred for myopathy who underwent repetitive nerve stimulation between January 2007 and May 2017. We included patients with decrement (>10%) and either a pathological or molecular diagnosis of myopathy. Results: Among 157 patients with myopathies, 4 patients had decrement (2 hydroxychloroquine‐associated vacuolar myopathy, 1 centronuclear myopathy, and 1 distal myopathy). One hydroxychloroquine‐associated vacuolar myopathy patient also had inflammatory myopathy. Pyridostigmine improved weakness in the centronuclear myopathy patient, but not in the distal myopathy patient. No patient with an acquired myopathy received pyridostigmine. Conclusions: Despite the rare occurrence of decrement in myopathy, its presence may urge consideration of pharmacological intervention. Muscle Nerve 59:475–478, 2019
Association Between Sphingolipids and Cardiopulmonary Fitness in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation
Saleem, Mahwesh, Herrmann, Nathan , Dinoff, Adam, Marzolini, Susan , Andreazza, Ana C. , Oh, Paul , Venkata, Swarajya Lakshmi Vattem, Andreazza, Ana C , Mielke, Michelle M. , Haughey, Norman J. , Lanctôt, Krista L.

Mayo Clinic

The Journals of Gerontology: Series A | December 8, 2018 | Volume: 75 | Issue: 4 | Pages: 671-679

10.1093/gerona/gly273 | PMID 30535238 Get It

Abstract The long-term benefits conferred by cardiac rehabilitation (CR) in those with coronary artery disease (CAD) are strongly linked with an improvement in cardiopulmonary fitness. This study aimed to determine the association between peripheral sphingolipids and cardiopulmonary fitness in CAD subjects undertaking CR. Patients with CAD (n = 100, mean age = 64 ± 6 years, 85% male, mean years of education = 17 ± 3 years) underwent 6 months of CR with blood collected at baseline, 3 and 6 months. Cardiopulmonary fitness was assessed by measuring peak oxygen uptake (VO2peak) at all time points. High performance liquid chromatography coupled electrospray ionization tandem mass spectrometry was used to quantify plasma sphingolipid concentrations. Cross-sectional and longitudinal associations between sphingolipids and VO2peak were assessed using linear regressions and mixed models, respectively. Higher concentrations of sphingomyelin C18:1 (β = −0.26, p = .01), ceramides C16:0 (β = −0.24, p = .02), C18:0 (β = −0.29, p = .002), C20:0 (β = −0.24, p = .02) and C24:1 (β = −0.24, p = .01) and monohexylceramide C18:0 (β = −0.23, p = .02) were associated with poorer VO2peak at baseline. An improvement in VO2peak was associated with a decrease in sphingomyelin C18:1 (b = −10.09, p = .006), ceramides C16:0 (b = −9.25, p = .0003), C18:0 (b = −5.44, p = .0003) and C24:1 (b = −2.46, p = .006) and monohexylceramide C18:0 (b = −5.37, p = .005). Specific long chain sphingolipids may be useful markers of fitness and response to exercise in CAD.
Regulatory Landscape in the United States
Vetter, Pamela L.

Mayo Clinic

Clinical Pharmacology & Therapeutics | December 8, 2018 | Volume: 105 | Issue: 1 | Pages: 26-28

10.1002/cpt.1243 | PMID 30536861 Get It

Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202
Dignam, James J., Hamstra, Daniel A. , Lepor, Herbert , Grignon, David J. , Brereton, Harmar D., Zeitzer, Kenneth L. , Venkatesan, Varagur, Horwitz, Eric M. , Pisansky, Thomas M. , Currey, Adam D. , Rosenthal, Seth A. , Sandler, Howard M.

Mayo Clinic

Journal of Clinical Oncology | December 7, 2018 | Volume: 37 | Issue: 3 | Pages: 213-221

10.1200/jco.18.00154 | PMID 30526194 Get It

Background In prostate cancer, end points that reliably portend prognosis and treatment benefit (surrogate end points) can accelerate therapy development. Although surrogate end point candidates have been evaluated in the context of radiotherapy and short-term androgen deprivation (AD), potential surrogates under long-term (24 month) AD, a proven therapy in high-risk localized disease, have not been investigated. Materials and Methods In the NRG/RTOG 9202 randomized trial (N = 1,520) of short-term AD (4 months) versus long-term AD (LTAD; 28 months), the time interval free of biochemical failure (IBF) was evaluated in relation to clinical end points of prostate cancer–specific survival (PCSS) and overall survival (OS). Survival modeling and landmark analysis methods were applied to evaluate LTAD benefit on IBF and clinical end points, association between IBF and clinical end points, and the mediating effect of IBF on LTAD clinical end point benefits. Results LTAD was superior to short-term AD for both biochemical failure (BF) and the clinical end points. Men remaining free of BF for 3 years had relative risk reductions of 39% for OS and 73% for PCSS. Accounting for 3-year IBF status reduced the LTAD OS benefit from 12% (hazard ratio [HR], 0.88; 95% CI, 0.79 to 0.98) to 6% (HR, 0.94; 95% CI, 0.83 to 1.07). For PCSS, the LTAD benefit was reduced from 30% (HR, 0.70; 95% CI, 0.52 to 0.82) to 6% (HR, 0.94; 95% CI, 0.72 to 1.22). Among men with BF, by 3 years, 50% of subsequent deaths were attributed to prostate cancer, compared with 19% among men free of BF through 3 years. Conclusion The IBF satisfied surrogacy criteria and identified the benefit of LTAD on disease-specific survival and OS. The IBF may serve as a valid end point in clinical trials and may also aid in risk monitoring after initial treatment.